These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 1382938)
21. Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication. Tönnesen KH; Albuquerque P; Baitsch G; Gomez Alonso A; Ibanez F; Kester RC; Leveson S; Poredos P Int Angiol; 1993 Dec; 12(4):371-7. PubMed ID: 8207316 [TBL] [Abstract][Full Text] [Related]
22. [Effect of indobufen on leukocyte-dependent thrombocyte aggregation in patients with ischemic heart disease]. Liusov VA; Diukov IV; Uteshev DV Kardiologiia; 1993; 33(4):22-3. PubMed ID: 7933785 [No Abstract] [Full Text] [Related]
23. The effect of indobufen on the thrombogenic potential of a Dacron prosthesis in an artificial circulation. Sheehan SJ; Monson JR; Salter MC; Rajah DS; Rajah SM; Kester RC Eur J Vasc Surg; 1988 Aug; 2(4):223-7. PubMed ID: 2975227 [TBL] [Abstract][Full Text] [Related]
24. [Long-term effects of indobufen on several parameters of blood platelet function in subjects at thrombotic risk]. Di Blasi S; Pintacuda S; Ferotti N; Lo Coco L; Muratore A; Russo G; Di Blasi U; D'Alessandro M; Morici G; Fornaciari M G Clin Med; 1990 Dec; 71(12):727-31. PubMed ID: 2150826 [TBL] [Abstract][Full Text] [Related]
25. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Fornaro G; Rossi P; Mantica PG; Caccia ME; Aralda D; Lavezzari M; Pamparana F; Milanesi G Circulation; 1993 Jan; 87(1):162-4. PubMed ID: 8419003 [TBL] [Abstract][Full Text] [Related]
26. [Evaluation of morning platelet aggregation in patients with ischemic cardiopathy after evening administration of indobufen]. Craveri A; Lanfredini M; Citella C; Braconaro F; Colombo L Minerva Cardioangiol; 1988 Sep; 36(9):411-8. PubMed ID: 3226570 [No Abstract] [Full Text] [Related]
27. Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease. Fabris F; Steffan A; Randi ML; Avruscio GP; Cordiano I; Girolami A J Med; 1992; 23(2):81-92. PubMed ID: 1512524 [TBL] [Abstract][Full Text] [Related]
28. Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: results of six months of treatment. Panchenko E; Eshkeeva A; Dobrovolsky A; Titaeva E; Podinovskaya Ya; Hussain KM; Karpov Yu Angiology; 1997 Mar; 48(3):247-54. PubMed ID: 9071201 [TBL] [Abstract][Full Text] [Related]
29. [Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial]. Rossini A; Tascino C; Costa F Minerva Cardioangiol; 1998 Nov; 46(11):457-69. PubMed ID: 10207294 [TBL] [Abstract][Full Text] [Related]
30. Endoscopic evaluation of the effects of indobufen and aspirin in healthy volunteers. Marzo A; Crestani S; Fumagalli I; Giusti A; Lowenthal DT Am J Ther; 2004; 11(2):98-102. PubMed ID: 14999361 [TBL] [Abstract][Full Text] [Related]
31. Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen. Fortunato JS; Pinheiro MJ; Monteiro MC; Rodrigues MA; Amaral I J Int Med Res; 1991; 19(4):305-17. PubMed ID: 1916004 [TBL] [Abstract][Full Text] [Related]
32. The dispositional enantioselectivity of indobufen in man. Strolm Benedetti M; Frigerio E; Tamassia V; Noseda G; Caldwell J Biochem Pharmacol; 1992 May; 43(9):2032-4. PubMed ID: 1596290 [TBL] [Abstract][Full Text] [Related]
33. A prostacyclin-sparing effect of indobufen vs. aspirin. De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417 [TBL] [Abstract][Full Text] [Related]
34. A double-blind placebo-controlled trial of indobufen in the prophylaxis of migraine. Carrieri PB; Orefice G; Sorge F Acta Neurol Scand; 1988 Jun; 77(6):433-6. PubMed ID: 3043994 [TBL] [Abstract][Full Text] [Related]
35. [Treatment with indobufen of platelet hyperaggregation in a group of patients with vascular diseases]. Barbieri U; Cappelli S; Zaniol P; Righi A; Artusi P; Scorrano M Minerva Med; 1991; 82(1-2):63-7. PubMed ID: 2000177 [TBL] [Abstract][Full Text] [Related]
36. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. Tran H; Anand SS JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585 [TBL] [Abstract][Full Text] [Related]
37. [Effect of treatment with indobufen on blood viscosity indices and exercise tolerance in patients with coronary disease]. Rdzanek H; Kochmański M; Zochowski RJ Wiad Lek; 1993 Apr; 46(7-8):245-9. PubMed ID: 8249409 [TBL] [Abstract][Full Text] [Related]
38. Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease. Chello M; Mastroroberto P; Celi V; Romano F; Marchese AR; Colonna A J Cardiovasc Pharmacol; 1996 Mar; 27(3):417-23. PubMed ID: 8907804 [TBL] [Abstract][Full Text] [Related]
39. The dispositional enantioselectivity of indobufen in rat and mouse. Strolin Benedetti M; Moro E; Frigerio E; Jannuzzo MG; Roncucci R; Caldwell J Biochem Pharmacol; 1990 Oct; 40(8):1719-23. PubMed ID: 2242009 [TBL] [Abstract][Full Text] [Related]
40. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. McTavish D; Faulds D; Goa KL Drugs; 1990 Aug; 40(2):238-59. PubMed ID: 2226215 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]